Main container

Studio di fase 3, randomizzato, controllato con placebo, in doppio cieco, su Vimseltinib per valutare l'efficacia e la sicurezza in pazienti affetti da tumore tenosinoviale a cellule giganti (MOTION)

Title
Studio di fase 3, randomizzato, controllato con placebo, in doppio cieco, su Vimseltinib per valutare l'efficacia e la sicurezza in pazienti affetti da tumore tenosinoviale a cellule giganti (MOTION)
Code
EudraCT
Type
Sperimentale
Start Year
2022
Status
In Corso

Principal Investigator

Operational unit that carry out the study

Documents and Videos attachament

You might also be interested in

Clinical Trial
A Phase 2/3, Randomized, Multicenter Study to Evaluate AL102 in Patients with Progressing Desmoid Tumors
Read more
Clinical Trial
Phase study 1/2 to evaluate palbociclib (IBRANCE®) in combination with irinotecan and temozolomide or in combination with topotecan and cyclophosphamide in pediatric patients with recurrent orrefractory solid tumors
Read more